Advancements in Pharmacology for Alzheimer's Disease: From Symptomatic Treatment to Disease-Modifying Drugs

Le résumé fourni par la source

Objective: The primary aim of this study is to evaluate the efficacy and safety of emerging disease-modifying therapies in Alzheimer's disease, comparing their effects with traditional symptomatic treatments. Methods: This randomized, double-blind, placebo-controlled trial enrolled 200 participants diagnosed with mild to moderate Alzheimer's disease. Participants were randomly assigned to one of four groups: (1) symptomatic treatment with Donepezil, (2) symptomatic treatment with Memantine, (3) disease-modifying therapy with a monoclonal anti-amyloid antibody (e.g., Aducanumab), or (4) placebo. The primary endpoint was the change in cognitive function, assessed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) over 12 months. Secondary outcomes included changes in functional status (Activities of Daily Living scale), quality of life (QoL-AD), and adverse events. Results: Cognitive Function: The disease-modifying therapy group showed a statistically significant reduction in ADAS-Cog scores compared to both symptomatic treatment and placebo groups (p < 0.05), indicating potential disease-modifying effects. Functional Status and Quality of Life: No significant differences were observed between symptomatic treatments and the placebo in improving functional status. However, patients in the disease-modifying group demonstrated improvements in the QoL-AD scores (p < 0.05). Adverse Events: Both symptomatic treatments and disease-modifying therapies were well tolerated. The most common adverse events in the disease-modifying therapy group were mild infusion-related reactions and headaches, which resolved over time. Conclusions: This study suggests that disease-modifying therapies targeting amyloid plaques may offer a promising approach to slowing cognitive decline in Alzheimer's disease. Although symptomatic treatments remain the mainstay of current care, disease-modifying drugs could transform the therapeutic landscape for AD, offering hope for halting or slowing disease progression. Larger, long-term studies are needed to confirm the durability of these effects and their potential role in clinical practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.